Αim of ImmunoSep is to assess whether personalized adjunctive immunotherapy directed against
a state of either fulminant hyper-inflammation or immunoparalysis is able to change sepsis
outcomes. Patients will be selected by a panel of biomarkers and laboratory findings and will
be allocated to placebo or immunotherapy treatment according to their needs.